These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3987792)

  • 21. Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.
    Birkett DJ; Miners JO; Attwood J
    Br J Clin Pharmacol; 1983 May; 15(5):567-9. PubMed ID: 6860533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two metabolites of sulphinpyrazone and their identification and determination by mass spectrometry.
    Jakobsen P; Pedersen AK
    J Pharm Pharmacol; 1981 Feb; 33(2):89-92. PubMed ID: 6111605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-performance liquid chromatographic analysis of sulfinpyrazone and its metabolites in biological fluids.
    Bjornsson TD; Wolfram KM; Routledge PA; Shand DG
    J Chromatogr; 1980 Mar; 181(3-4):417-25. PubMed ID: 7391155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of the pharmacokinetics of antithrombotic drugs.
    Marks GS
    Thromb Res Suppl; 1983; 4():17-27. PubMed ID: 6356463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma levels and pharmacokinetics of sulphinpyrazone in renal impairment during chronic treatment: a case report.
    Godbillon J; Schoeller JP; Gauron S; Gosset G; Fillastre JP
    Br J Clin Pharmacol; 1984 Jul; 18(1):107-8. PubMed ID: 6743484
    [No Abstract]   [Full Text] [Related]  

  • 26. Determination of bioavailability and systemically available fractions of drugs undergoing reversible metabolism: application to 4-amino-5-chloro-2-[2-(methylsulfinyl)ethoxy]-N-[2- (diethylamino)ethyl]benzamide and its sulfide and sulfone metabolites in rats.
    Kuo BS; Poole JC; Hwang KK; Cheng H
    J Pharm Sci; 1994 Mar; 83(3):386-90. PubMed ID: 8207687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isomazole disposition in man as a function of dose and route of administration.
    Woodworth JR; Delong AF; Fasola AF; Oldham S
    Biopharm Drug Dispos; 1991 Dec; 12(9):673-86. PubMed ID: 1790312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years.
    Walter E; Staiger C; de Vries J; Weber E; Bitzer W; Degott M; Jüngling K
    Klin Wochenschr; 1982 Nov; 60(22):1409-13. PubMed ID: 6129344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of the effect of sulphinpyrazone ('Anturan') on blood viscosity.
    Johnston RV; Lowe GD; Drummond MM; Forbes CD; Prentice CR
    Curr Med Res Opin; 1979; 6(4):271-3. PubMed ID: 527353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.
    Pedersen AK; Jakobsen P; Kampmann JP; Hansen JM
    Clin Pharmacokinet; 1982; 7(1):42-56. PubMed ID: 7042172
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers.
    Pfister B; Imhof P; Wirz H
    Eur J Clin Pharmacol; 1978 Jun; 13(4):263-5. PubMed ID: 668783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiologic and antiarrhythmic actions of sulphinpyrazone and its sulfide metabolite G25671.
    Eller BT; Lynch JJ; Patterson E; Lucchesi BR
    Pharmacology; 1987; 34(2-3):121-30. PubMed ID: 3108907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
    Nunn B; James FJ
    Br J Clin Pharmacol; 1980 Mar; 9(3):239-45. PubMed ID: 7362733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandin-kallikrein-renin system during acute sulphinpyrazone administration in healthy volunteers.
    Verschueren LJ; Boelaert J; Daneels R; Schurgers M; Van Eeghem P; Lijnen P; Amery A
    Methods Find Exp Clin Pharmacol; 1982; 4(6):425-9. PubMed ID: 6755104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics.
    Malloy MJ; Ravis WR; Pennell AT; Hagan DR; Betagari S; Doshi DH
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):286-9. PubMed ID: 7921528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of chronic metoprolol and sulphinpyrazone on human lymphocyte beta-adrenoceptors.
    De Blasi A; Cortellaro M; Costantini C
    Br J Clin Pharmacol; 1984 Jul; 18(1):45-50. PubMed ID: 6331481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism and pharmacokinetics of dothiepin.
    Maguire KP; Burrows GD; Norman TR; Scoggins BA
    Br J Clin Pharmacol; 1981 Sep; 12(3):405-9. PubMed ID: 7295471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of alprazolam. Therapeutic implications.
    Greenblatt DJ; Wright CE
    Clin Pharmacokinet; 1993 Jun; 24(6):453-71. PubMed ID: 8513649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
    Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
    Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.